Your browser doesn't support javascript.
loading
Nonaggressive systemic mastocytosis (SM) without skin lesions associated with insect-induced anaphylaxis shows unique features versus other indolent SM.
Alvarez-Twose, Iván; Zanotti, Roberta; González-de-Olano, David; Bonadonna, Patrizia; Vega, Arantza; Matito, Almudena; Sánchez-Muñoz, Laura; Morgado, José Mário; Perbellini, Omar; García-Montero, Andrés; De Matteis, Giovanna; Teodósio, Cristina; Rossini, Maurizio; Jara-Acevedo, María; Schena, Donatella; Mayado, Andrea; Zamò, Alberto; Mollejo, Manuela; Sánchez-López, Paula; Cabañes, Nieves; Orfao, Alberto; Escribano, Luis.
Afiliación
  • Alvarez-Twose I; Instituto de Estudios de Mastocitosis de Castilla La Mancha (CLMast), Hospital Virgen del Valle, Toledo, Spain; Spanish Network on Mastocytosis (REMA), Toledo and Salamanca, Spain. Electronic address: ivana@sescam.jccm.es.
  • Zanotti R; Section of Haematology, Department of Medicine, University of Verona, Verona, Italy; Multidisciplinary Outpatients Clinics for Mastocytosis, Verona, Italy.
  • González-de-Olano D; Spanish Network on Mastocytosis (REMA), Toledo and Salamanca, Spain; Allergy Unit, Hospital de Fuenlabrada, Madrid, Spain.
  • Bonadonna P; Multidisciplinary Outpatients Clinics for Mastocytosis, Verona, Italy; Allergy Unit, Azienda Ospedaliera Universitaria Integrata, Verona, Italy.
  • Vega A; Allergy Department, Hospital de Guadalajara, Guadalajara, Spain.
  • Matito A; Instituto de Estudios de Mastocitosis de Castilla La Mancha (CLMast), Hospital Virgen del Valle, Toledo, Spain; Spanish Network on Mastocytosis (REMA), Toledo and Salamanca, Spain.
  • Sánchez-Muñoz L; Instituto de Estudios de Mastocitosis de Castilla La Mancha (CLMast), Hospital Virgen del Valle, Toledo, Spain; Spanish Network on Mastocytosis (REMA), Toledo and Salamanca, Spain.
  • Morgado JM; Instituto de Estudios de Mastocitosis de Castilla La Mancha (CLMast), Hospital Virgen del Valle, Toledo, Spain; Spanish Network on Mastocytosis (REMA), Toledo and Salamanca, Spain.
  • Perbellini O; Section of Haematology, Department of Medicine, University of Verona, Verona, Italy; Multidisciplinary Outpatients Clinics for Mastocytosis, Verona, Italy.
  • García-Montero A; Spanish Network on Mastocytosis (REMA), Toledo and Salamanca, Spain; Centro de Investigación del Cáncer/IBMCC (USAL/CSIC) and IBSAL, Departamento de Medicina and Servicio General de Citometría, University of Salamanca, Salamanca, Spain.
  • De Matteis G; Multidisciplinary Outpatients Clinics for Mastocytosis, Verona, Italy; Clinical Chemistry and Haematology, Azienda Ospedaliera Universitaria Integrata, Verona, Italy.
  • Teodósio C; Spanish Network on Mastocytosis (REMA), Toledo and Salamanca, Spain; Centro de Investigación del Cáncer/IBMCC (USAL/CSIC) and IBSAL, Departamento de Medicina and Servicio General de Citometría, University of Salamanca, Salamanca, Spain.
  • Rossini M; Multidisciplinary Outpatients Clinics for Mastocytosis, Verona, Italy; Section of Rheumatology, Department of Medicine, Azienda Ospedaliera Universitaria Integrata, Verona, Italy.
  • Jara-Acevedo M; Spanish Network on Mastocytosis (REMA), Toledo and Salamanca, Spain; Centro de Investigación del Cáncer/IBMCC (USAL/CSIC) and IBSAL, Departamento de Medicina and Servicio General de Citometría, University of Salamanca, Salamanca, Spain.
  • Schena D; Multidisciplinary Outpatients Clinics for Mastocytosis, Verona, Italy; Section of Dermatology, Department of Medicine, Azienda Ospedaliera Universitaria Integrata, Verona, Italy.
  • Mayado A; Spanish Network on Mastocytosis (REMA), Toledo and Salamanca, Spain; Centro de Investigación del Cáncer/IBMCC (USAL/CSIC) and IBSAL, Departamento de Medicina and Servicio General de Citometría, University of Salamanca, Salamanca, Spain.
  • Zamò A; Multidisciplinary Outpatients Clinics for Mastocytosis, Verona, Italy; Department of Pathology, Azienda Ospedaliera Universitaria Integrata, Verona, Italy.
  • Mollejo M; Spanish Network on Mastocytosis (REMA), Toledo and Salamanca, Spain; Pathology Department, Hospital Virgen de la Salud, Toledo, Spain.
  • Sánchez-López P; Allergy Unit, Hospital Virgen del Valle, Toledo, Spain.
  • Cabañes N; Allergy Unit, Hospital Virgen del Valle, Toledo, Spain.
  • Orfao A; Spanish Network on Mastocytosis (REMA), Toledo and Salamanca, Spain; Centro de Investigación del Cáncer/IBMCC (USAL/CSIC) and IBSAL, Departamento de Medicina and Servicio General de Citometría, University of Salamanca, Salamanca, Spain.
  • Escribano L; Spanish Network on Mastocytosis (REMA), Toledo and Salamanca, Spain.
J Allergy Clin Immunol ; 133(2): 520-8, 2014 Feb.
Article en En | MEDLINE | ID: mdl-23921094
ABSTRACT

BACKGROUND:

Indolent systemic mastocytosis (ISM) without skin lesions (ISMs(-)) shows a higher prevalence in males, lower serum baseline tryptase levels, and KIT mutation more frequently restricted to bone marrow (BM) mast cells (MCs) than ISM with skin lesions (ISMs(+)). Interestingly, in almost one-half of ISMs(-) patients, MC-mediator release episodes are triggered exclusively by insects.

OBJECTIVE:

We aimed to determine the clinical and laboratory features of ISMs(-) associated with insect-induced anaphylaxis (insectISMs(-)) versus other patients with ISM.

METHODS:

A total of 335 patients presenting with MC activation syndrome, including 143 insectISMs(-), 72 ISMs(-) triggered by other factors (otherISMs(-)), 56 ISMs(+), and 64 nonclonal MC activation syndrome, were studied.

RESULTS:

Compared with otherISMs(-) and ISMs(+) patients, insectISMs(-) cases showed marked male predominance (78% vs 53% and 46%; P < .001), a distinct pattern of MC-related symptoms, and significantly lower median serum baseline tryptase levels (22.4 vs 28.7 and 45.8 µg/L; P ≤ .009). Moreover, insectISMs(-) less frequently presented BM MC aggregates (46% vs 70% and 81%; P ≤ .001), and they systematically showed MC-restricted KIT mutation.

CONCLUSIONS:

ISMs(-) patients with anaphylaxis triggered exclusively by insects display clinical and laboratory features that are significantly different from other ISM cases, including other ISMs(-) and ISMs(+) patients, suggesting that they represent a unique subgroup of ISM with a particularly low BM MC burden in the absence of adverse prognostic factors.
Asunto(s)
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Enfermedades de la Piel / Avispas / Abejas / Mastocitosis Sistémica / Anafilaxia / Mordeduras y Picaduras de Insectos Tipo de estudio: Diagnostic_studies / Prognostic_studies / Risk_factors_studies Límite: Adolescent / Adult / Aged / Aged80 / Animals / Female / Humans / Male / Middle aged Idioma: En Revista: J Allergy Clin Immunol Año: 2014 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Enfermedades de la Piel / Avispas / Abejas / Mastocitosis Sistémica / Anafilaxia / Mordeduras y Picaduras de Insectos Tipo de estudio: Diagnostic_studies / Prognostic_studies / Risk_factors_studies Límite: Adolescent / Adult / Aged / Aged80 / Animals / Female / Humans / Male / Middle aged Idioma: En Revista: J Allergy Clin Immunol Año: 2014 Tipo del documento: Article